“What’s new in therapeutics?” will examine and evaluate drugs that may have a place in hospice, palliative, and long-term care. Mirtazepine will be examined and evaluated. Mirtazepine is a potential alternative anti-depressant with multiple additional benefits. It is an atypical anti-depressant, which has both noradrenergic and specific serotonergic receptor antagonism (NaSSa), and a unique pharmacological profile. Mirtazepine appears to be a “designer drug” for palliative medicine with a number of benefits, but cost may be a drawback.
Abed RT, Cooper M: Mirtazepine causing hyperphagia. British J Psychiatry. 1999; 174(2): 181-182.
2.
Bailer U, Praschak-Reider N, Pezawas L, Kasper S: Mirtazepine in inpatient treatment of depressed patients. Wien Klin Wochenschr. 1998; 110(18): 646-650.
3.
Brannon GE, Stone KD: The use of mirtazapine in a patient with chronic pain. J Pain & Symptom Manage. 1999; 18(5): 382-385.
4.
Burrows GD, Kremer CM: Mirtazapine: Clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997; 1: 34-39.
5.
Curran S, de Pauw K: Selecting an antidepressant for use in a patient with epilepsy: Safety considerations. Drug Safety. 1998; 18(2): 125-133.
6.
de Boer TH: The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996; 57:19-25.
7.
Gelenberg AJ, Laukes C, McGahuy C, et al.: Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry. 2000; 61(5): 356-360.
8.
Kent JM: SNaRIs, NaSSAS, and NaRIs: New agents for the treatment of depression. Lancet. 2000; 355: 911-918.
9.
O’Reardon JP, Brunswick DJ, Amsterdam JD: Treatment-resistant depression in the age of serotonin: Evolving strategies. Current Opinion in Psychiatry. 2000; 13(1): 93-98.
10.
Puzantian T: Mirtazapine, an antidepressant. American J Health-System Pharmacy. 1998; 55(1): 44-49.
